Research advances in mechanism and clinical application of anti-angiogenesis therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer

The use of immunotherapy has revolutionized the treatment of patients with non-small cell lung cancer (NSCLC) in recent years. Anti-angiogenic agents can induce tumor vessel normalization and promote the infiltration of immune effector cells, which may synergize with immune checkpoint inhibitors (ICIs). In this paper, the mechanisms of anti-angiogenic agents combined with ICIsare illustrated, and relevant clinical studies are summarized and analyzed, in order to provide more treatment options for NSCLC patients.